Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A1811 (Trastuzumab Rezetecan) in Advanced HER2-Expressing/Mutated Solid Tumors
NCT04446260Phase 1Completed
- Sponsor
- Hengrui
- Start
- Sep 2020
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of trastuzumab rezetecan in solid tumor (3 arms), sponsored by Hengrui. Primary endpoint: Incidence and severity of adverse events (AEs). Started Sep 2020; status: completed.
02
Drugs
trastuzumab rezetecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04446260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04446260.